Rapid Micro Biosystems (RPID) Q3 2026 earnings review
Rapid Micro's sales rise, and Germany's Merck plans a takeover
Rapid Micro Biosystems, which automates microbe tests for drug makers, earns far more per sale but has little cash left. Sales rose 22%, and gross margin reached a record 25%, chief executive Rob Spignesi said. Cash shrank to about $7 million, so the agreement to sell the business to Germany's Merck KGaA matters more than the quarter.
| Revenue | $9.5M $7.8M a year ago |
|---|---|
| Gross margin | 25.2% 8.9% a year ago |
| Systems validated by customers | 12 4 a year ago |
| Full-year outlook | Withdrawn was $37โ41M of revenue |
โ๏ธ Verdict: ๐ข Bullish
The story got better, because the planned margin gains arrived on time and a buyer now offers an answer to the cash problem. The bad news: recurring revenue from supplies and service rose just 7%, even as customers put far more systems to work.
The question now is whether the Merck KGaA deal closes before Rapid Micro needs new money. If it closes, Merck KGaA funds the margin plan; if it fails, the smaller company must borrow or sell shares quickly. The delayed quarterly filing and the tender offer documents will tell.
๐ Bull Case
Gross Margin Reaches a Record 25%
Rapid Micro sells the Growth Direct system, which automates the microbe tests drug factories run, plus its supplies and service. Chief executive Rob Spignesi credited the "continued progress in our gross margin expansion initiatives". The bear case held that this plan could slip, as the 2025 margin plan did.
This quarter the plan held. Cost of revenue, what Rapid Micro spends to build and service its systems, barely moved while sales rose 22%.
- Total gross margin: 25.2%, against 8.9% a year ago
- Cost of revenue: 74.8% of sales, down 16.3 percentage points
- Product gross margin: 12.1%, against minus 6.7%
- Service gross margin: 53.6%, against 39.8%
This matters because product margin sat below zero in every earlier quarter we can measure, so systems sold at a loss. But one quarter does not prove management's target of 50% gross margin by the end of 2028, and no full-year plan now backs the next step.
What to watch: fourth-quarter gross margin, due with the annual results. A level near this quarter's would show the vendor cost cuts agreed last year still hold in the busiest quarter.
Customers Finished Setting Up 12 Systems
A customer validates a Growth Direct system, approving it for daily use in its plant, before buying test supplies for it. Rapid Micro's filings treat validated systems as a leading sign of future recurring revenue.
- Validations completed: 12, against four a year ago
- Systems placed with customers: seven, against five
- Validated systems in use: about 181 by our math, up 19%
- Placed but not yet validated: about 26 by our math, from 31 in June
Validations cleared the plan's floor of 10, and placements matched its floor of seven. So the queue that built up after last year's large Amgen order is turning into working systems.
What to watch: recurring revenue in the fourth quarter, the first full quarter of supply orders from many of these systems. Growth in that line would show the new systems are buying.
Positives this quarter didn't test
Two standing positives got no new evidence, because Rapid Micro held no call and published no outlook with these results.
- Long-term targets: management's 2028 goals for gross margin and positive cash flow got no update; the Merck KGaA deal may replace them.
- Demand for automated testing, especially from contract drug makers: no comment this quarter; new multi-system orders would move it.
๐ป Bear Case
Cash Dropped to About $7 Million
Rapid Micro has lost money every quarter, so its cash decides how long it can operate alone. Spignesi presented the sale to Merck KGaA as a way to "significantly expand the Growth Direct's reach".
The balance sheet tells a more pressing story. Cash and short-term investments fell by about $13 million in the quarter. At that pace, what remains would not cover another quarter.
- Cash and short-term investments: $6.7 million, against $19.8 million in June
- Loan from Trinity Capital: $19.2 million
- Debt minus cash: about $12.2 million by our math, against net cash a year ago
- Shareholders' equity: $8.8 million, against $33.2 million in December
This cuts against the growth framing, because Rapid Micro needed money soon with or without a buyer. Its lender would release the next $10 million only if second-half sales and margin targets held, and the company has now withdrawn its full-year plan.
What to watch: the delayed quarterly filing, due within the extension period. Its cash note should show how long the business can run before the deal closes.
Repeat Sales Grew Only 7%
Recurring revenue is the steady income from test supplies and service contracts, and it should track every system customers put to work. It rose 6.9%, the weakest pace in five quarters.
- Recurring share of sales: 55%, against 61% a year ago
- Recurring revenue per validated system: about $28,700 a quarter by our math, near the low end of two years
- Systems and other one-time sales: up 42% by our math
So growth came from selling and installing systems, which happen once. Rapid Micro's long-term plan rests on supplies, which repeat, and the release gives no figure for supplies alone.
What to watch: recurring revenue next quarter against the growing base of validated systems. Growth below the base's pace would mean each system buys fewer supplies.
Risks this quarter didn't answer
Several standing risks got no clear answer, because the release came with no call, no outlook and no quarterly filing this time.
- Fourth-quarter placements: the withdrawn plan left the largest share of the year's systems for the final quarter; the annual report will show the count.
- Product margin: above zero this quarter for the first time we can measure, but one quarter and no outlook cannot settle it.
- MilliporeSigma, the Merck KGaA unit that distributes Growth Direct: no count of systems it bought against its minimum commitment.
- New shares and warrants: the May share sale left warrants on about 12.3 million shares; the tender terms will decide them.
- Customer concentration: the delayed filing holds the customer tables.
- US reshoring of drug production: the release does not mention it.
๐ Other Themes
Merck KGaA Agreed to Buy Rapid Micro
Rapid Micro signed a definitive agreement for Merck KGaA, the German science group, to buy all its shares through a tender offer. Merck KGaA's MilliporeSigma unit already distributes Growth Direct systems. Spignesi cited "a strong partnership with Merck KGaA, Darmstadt, Germany" built over 18 months. Rapid Micro put the deal terms in a separate release, cancelled its earnings call and delayed its quarterly filing.
Cost Programme Added a $0.7 Million Charge
Operating expenses rose 8.1%, and a one-time charge for the "focused efficiency program" Rapid Micro started in August added $0.7 million. Without the charge, spending grew about 2% by our math. Research spending fell 15.8%, while general and administrative costs climbed 12.2%.
๐ฒ Other KPIs
Money customers owe Rapid Micro climbed 41% from a year ago, about twice the pace of sales. Receivables now equal 80% of the quarter's sales, against 69% a year ago. In June the ratio stood at 68%. Slower collection would add strain to a thin cash position.
Deferred revenue, cash customers paid in advance for service not yet delivered, fell 12.9% from a year ago and 19.9% from June. It has declined from $6.6 million in March, even as more systems came into use, so fewer customers are paying ahead.
The share count rose 8.7% from a year ago, mainly after the May share sale to large existing holders. Growth was 3.3% in March. The loss per share narrowed to $0.23 from $0.26, partly because the same loss spreads across more shares.
The operating loss before interest, depreciation, stock pay and the restructuring charge, which Rapid Micro calls adjusted EBITDA loss, narrowed 15.7% from a year ago. In June it had widened to $10.3 million. Higher gross profit did most of the work.
๐ฎ Guidance
Withdrawn. Rapid Micro dropped its full-year plan because of the Merck KGaA deal, so no sales outlook remains. By our math, the old range needed $11.4โ15.4 million in the fourth quarter. The middle of it pointed to about 19% growth over last year's record fourth quarter, a touch below this quarter's pace.
Withdrawn. The plan had called for gross margin of about 20% for the year. Nine-month gross margin stands at 15.6%. By our math, the fourth quarter needed about 28% at the middle of the sales range, above this quarter's record.
Withdrawn. The plan had called for 30 to 38 system placements this year. Customers took 17 through September. By our math, that left 13 to 21 for the fourth quarter. Last year's fourth quarter, helped by the large Amgen order, delivered 16.
Withdrawn. In August the plan had lifted the target to at least 27 validations this year. Customers had completed 26 by September. So one more in the fourth quarter would have met it.
โ Key Questions
When will the Merck KGaA deal close?
Cash and short-term investments fell to about $7 million. The closing date decides whether Rapid Micro must borrow or raise money before the deal completes.
Can Rapid Micro still draw the next Trinity loan?
The lender tied the next $10 million to second-half sales and margin targets. With the full-year plan withdrawn, Rapid Micro has not said whether it still expects to meet them.
How much do test supplies alone bring in?
Rapid Micro gives only growth rates for supplies. Dollar figures would show whether the slowdown in recurring revenue comes from supplies or from service contracts.
How many systems did MilliporeSigma buy this year?
The Merck KGaA unit has a minimum purchase commitment. Its actual purchases show how much the partnership adds to sales today, before any takeover.
What happens to the May warrants in the deal?
The May share sale came with warrants on about 12.3 million shares. The tender terms decide what those holders receive and how many shares Merck KGaA must buy.
